This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Journal of Hematology & Oncology Open Access 24 March 2022
-
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
Journal of Hematology & Oncology Open Access 06 April 2021
-
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Clinical Epigenetics Open Access 07 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Marschalek R . Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011; 152: 141–154.
Cox MC, Panetta P, Lo-Coco F, Del Poeta G, Venditti A, Maurillo L et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol 2004; 122: 298–306.
Zhang Y, Chen A, Yan XM, Huang G . Disordered epigenetic regulation in MLL-related leukemia. Int J Hematol 2012; 96: 428–437.
Slany RK . The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984–993.
So CW, Lin M, Ayton PM, Chen EH, Cleary ML . Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003; 4: 99–110.
Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML . The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005; 123: 207–218.
Grembecka J, Belcher AM, Hartley T, Cierpicki T . Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem 2010; 285: 40690–40698.
Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T et al. Structural insights into inhibition of the bivalent menin–MLL interaction by small molecules in leukemia. Blood 2012; 120: 4461–4469.
Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S et al. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood 2014; 124: 263–272.
Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41–47.
Wang QF, Wu G, Mi S, He F, Wu J, Dong J et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011; 117: 6895–6905.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20: 66–78.
Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147–2154.
Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J et al. Pharmacologic inhibition of the Menin–MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 2015; 27: 589–602.
Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ et al. Menin–MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012; 8: 277–284.
Acknowledgements
This work was supported by the National Institute of Health grant R01 (1R01CA160467) to JG, a Leukemia and Lymphoma Society (LLS) TRP grant (6116–12) and the LLS Therapy Acceleration Program to JG, LLS Scholar (1215–14) to JG, American Cancer Society grants (RSG-11-082-01-DMC to TC and RSG-13-130-01-CDD to JG) and the Department of Pathology, the University of Michigan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Drs Grembecka and Cierpicki received research support from Kura Oncology. They are also receiving compensation as members of the scientific advisory board of Kura Oncology, and they have an equity ownership in the company. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
He, S., Malik, B., Borkin, D. et al. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner. Leukemia 30, 508–513 (2016). https://doi.org/10.1038/leu.2015.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.144
This article is cited by
-
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Journal of Hematology & Oncology (2022)
-
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
Journal of Hematology & Oncology (2021)
-
Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches
Current Hematologic Malignancy Reports (2021)
-
The genomics of acute myeloid leukemia in children
Cancer and Metastasis Reviews (2020)
-
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Clinical Epigenetics (2019)